Overall, phosphoflow cytometry findings in melanoma patients indicate that signaling, as measured by p-STAT1 and p-STAT3 expression, can potentially be used to predict patient response to high-dose IFN-α and nivolumab therapies, respectively, with increased signaling correlating with better treatment response. The gene discussed is STAT1; the disease is melanoma.